Dihydrooxadiazinones

US12258323B2 · kind B2 · utility

Assignees

• BAYER HEALTHCARE LLC · DE
• Bayer Pharma Aktiengesellschaft · DE
• The Broad Institute, Inc. · US
• DANA-FARBER CANCER INSTITUTE, INC. · US

Inventors

• Manuel Ellermann · Berlin, DE
• Stefan Nikolaus Gradl · Berlin, DE
• Charlotte Christine Kopitz · Falkensee, DE
• Martin Lange · Berlin, DE
• Adrian Tersteegen · Wuppertal, DE
• Philip Lienau · Berlin, DE
• Christa Hegele-Hartung · Mülheim an der Ruhr, DE
• Detlev Sülzle · Berlin, DE
• Timothy A. Lewis · Marlborough, US
• Heidi Greulich · Cambridge, US
• Xiaoyun Wu · Chesterfield, US
• Matthew Meyerson · Concord, US
• Alex Burgin · Cambridge, US

Key dates

• Filing date: Jul 11, 2022
• Grant date: Mar 25, 2025
• Expiry date: Jul 11, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D495/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.